Blog - Crystal Pharmatech Co., Ltd.

Whitepaper Technical Insight Blog Case Study Presentation

Blog

Solubility Enhancement Strategies for BCS Class II and IV Drugs: Which Levers Actually Change Developability

A practical framework for comparing amorphous dispersions, nanocrystals, lipid systems, salts, and co-crystals based on how each approach changes the development profile for poorly soluble oral drugs.

14 Apr 2026



Blog

Developing Controlled Substances in CMC: Where Solid Form, Containment, and Supply Planning Intersect

This blog examines controlled-substance development from a CMC perspective, with emphasis on how solid form, containment, and supply assumptions can begin interacting earlier than many teams expect. F...

08 Apr 2026



Blog

Solubility vs. Supersaturation: Why Apparent Solubility Can Mislead Your Development Decisions

This practical CMC guide explains how apparent solubility, true thermodynamic solubility, and supersaturation differ, and why that distinction matters for solid form selection, dissolution method design, and formulation strategy.

02 Apr 2026



Blog

Predicting Solid-Form Change Under Real-World Humidity and Temperature Conditions

This practical CMC guide shows how humidity and temperature together affect solid forms, influence stability and manufacturability, and support better study design, control strategies, and packaging decisions

26 Mar 2026



Blog

Mini-Tablet, Major Impact: From Lab to Commercial Scale

Crystal Pharmatech’s integrated mini-tablet platform accelerates development from lab to commercial scale. We provide precision engineering, 505(b)(2) expertise, and high-precision filling for APIs.

25 Mar 2026



Blog

Short Half-Life vs. Once-a-Day Dosing: Breaking the Barrier

A short half-life doesn't rule out QD dosing. By leveraging Modified Release (MR) to flatten PK curves and addressing pillars like absorption windows and solubility, developers can bridge the gap from IR to once-daily regimens, ensuring patient compliance and therapeutic differentiation.

18 Mar 2026



Blog

The Race to FIH: How Fast Can You Reach the Clinic?

We want to move fast to first-in-human. How quickly can formulation and clinical supply be ready for IND?In the high-stakes world of drug development, speed is the ultimate currency. But as the saying...

12 Mar 2026



Blog

Peptide Crystallization Process Development: A Practical CMC Guide for Peptide APIs

Peptide crystallization process development can transform peptide API stability, filtration, and downstream manufacturability. Learn high-throughput screening, salt and polymorph screening, seeding, a...

11 Mar 2026



Blog

Conquering the “Uncrystallizable”: Advanced Strategies for PROTAC Solid-Form Development

In the world of drug development, PROTACs (Proteolysis Targeting Chimeras) are notoriously difficult to crystallize. Their high molecular weight, inherent flexibility, and complex surface area often l...

10 Mar 2026



Blog

The “Double-Limited” Challenge: Is ASD Always the Answer?

When a compound is both solubility and permeability limited, the reflex is often to reach for ASD. But is that always the right move? We walk through the systematic framework our team uses to find the true bottleneck.

05 Mar 2026

